Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders

NVCR

NEW YORK, July 18, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws.

Class Period: January 5, 2023 to June 5, 2023
Lead Plaintiff Deadline: August 18, 2023
No obligation or cost to you.

Learn more about your recoverable losses in NVCR:
https://www.kleinstocklaw.com/pslra-1/novocure-lawsuit-loss-submission-form?id=42200&from=4

NovoCure Limited NEWS - NVCR NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that NovoCure Limited made materially false and/or misleading statements and/or failed to disclose that: (i) the Company concealed the true nature of the LUNAR study data, including that the study relied on a relatively small percentage of study participants that had been receiving standard of care therapy; (ii) as a result, the data was materially less reliable in terms of demonstrating clinical efficacy; (iii) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company's regulatory prospects and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in NovoCure you have until August 18, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased NovoCure securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the NVCR lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/novocure-lawsuit-loss-submission-form?id=42200&from=4.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
jk@kleinstocklaw.com
Telephone: (212) 616-4899
www.kleinstocklaw.com

Cision View original content:https://www.prnewswire.com/news-releases/nvcr-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-august-18-2023-in-the-class-action-filed-on-behalf-of-novocure-limited-shareholders-301879092.html

SOURCE The Klein Law Firm



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today